- $33.73m
- $1.51bn
- $749.63m
- 52
- 86
- 68
- 77
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.74% | ||
| Return on Equity | n/a | ||
| Operating Margin | -18.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 154.78 | 221.04 | 245.63 | 421.08 | 749.63 | 741.39 | 784.55 | 59.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Akumin Inc. is a provider of radiology and oncology services to health systems, hospitals, physician groups, and patients all across the country. The Company operates through two segments: Radiology and Oncology. The Company provides fixed-site outpatient diagnostic imaging services through a network of approximately 180 owned and/or operated imaging locations, and outpatient radiology and oncology services and solutions to approximately 1,000 hospitals and health systems across 48 states. Its imaging procedures include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography and other related procedures. Its cancer care services include a full suite of radiation therapy and related offerings. Its services include radiology exams, radiology technology, radiology subspecialties, oncology conditions treated and oncology radiation therapy.
Directors
- Stanley Dunford CHM (72)
- Riadh Zine PRE (49)
- Mohammad Saleem CFO
- Leigh Fernandes CEX
- Kevin Johnson CEX
- Michael Meredith CEX
- Rohit Navani COO
- Matthew Cameron SVP
- Darren Speed CCO
- Lori Marker VPR
- Adam Fabian CTR
- Christopher Fitzgerald OTH
- Laura Kassa OTH
- Michael Luckey OTH
- Jason Richardson OTH
- Murray Lee LED (61)
- Thomas Davies IND (62)
- James Webb IND (61)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- September 30th, 2022
- Public Since
- December 1st, 2017
- No. of Shareholders
- 84
- No. of Employees
- 3,631
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 91,173,491
- Address
- 8300 W Sunrise Blvd, PLANTATION
- Web
- Phone
- +1 9546784489
- Auditors
- Ernst & Young LLP
Upcoming Events for AKUMQ
Q1 2024 Akumin Inc Earnings Release
Akumin Inc Annual Shareholders Meeting
Similar to AKUMQ
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
ACI Global
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
FAQ
What is the Akumin share price?
As of Today at 18:02 UTC, shares in Akumin are trading at $0.37. This share price information is delayed by 15 minutes.
How has the Akumin share price performed this year?
Shares in Akumin last closed at $0.37 and the price had moved by -61.05% over the past 365 days. In terms of relative price strength the Akumin share price has underperformed the S&P500 Index by -65.1% over the past year.
What are the analyst and broker recommendations for Akumin?
The overall consensus recommendation for Akumin is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Akumin dividend yield?
Akumin does not currently pay a dividend.
Does Akumin pay a dividend?
Akumin does not currently pay a dividend.
When does Akumin next pay dividends?
Akumin does not currently pay a dividend.
How do I buy Akumin shares?
To buy shares in Akumin you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Akumin?
As of the previous close price of $0.37, shares in Akumin had a market capitalisation of $33.73m.
Where are Akumin shares listed?
Here are the trading details for Akumin:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AKUMQ
What kind of share is Akumin?
Based on an overall assessment of its quality, value and momentum Akumin is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Akumin share price forecast for 2024?
The analyst consensus target price for shares in Akumin is $0.89. That is 141.87% above the last closing price of $0.37.
Analysts covering Akumin currently have a consensus Earnings Per Share (EPS) forecast of -$2.21 for the next financial year.
What is the trend in the Akumin share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akumin. Over the past six months, its share price has outperformed the S&P500 Index by +94.66%.
As of the last closing price of $0.37, shares in Akumin were trading +27.76% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Akumin PE Ratio?
The Akumin PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Akumin?
Akumin's management team is headed by:
- Stanley Dunford - CHM
- Riadh Zine - PRE
- Mohammad Saleem - CFO
- Leigh Fernandes - CEX
- Kevin Johnson - CEX
- Michael Meredith - CEX
- Rohit Navani - COO
- Matthew Cameron - SVP
- Darren Speed - CCO
- Lori Marker - VPR
- Adam Fabian - CTR
- Christopher Fitzgerald - OTH
- Laura Kassa - OTH
- Michael Luckey - OTH
- Jason Richardson - OTH
- Murray Lee - LED
- Thomas Davies - IND
- James Webb - IND